Table 4. Median CAC progression, expressed by CAC volume score, for late versus premature family history of CHD and stratified by race/ethnicity.

Fam Hx Category	Model 1		Model 2		Model 3
	β (95% CI) CAC Score	p value	β (95% CI) CAC Score	p value	β (95% CI) CAC Score	p value
No Family History	1 (Reference)		1 (Reference)		1 (Reference)
Overall
Late	8.17(1.12-15.22)*	0.023	8.11(1.61-14.62)*	0.01	-1.45 (-8.93-6.03)	0.70
Premature	16.69 (8.33-25.05)*	<0.001	14.44(6.13-22.42)*	<0.001	4.35 (-4.52-13.21)	0.34
Whites
Late	8.20 (-3.47-21.11)	0.16	10.98 (0.60-21.90)	0.05	-1.62(-12.95-9.71)	0.78
Premature	27.76 (12.76-2.76)*	<0.001	21.32(7.84-34.81)*	0.002	14.22(0.22-28.23)*	0.046
Chinese
Late	7.35 (-13.84-28.54)	0.50	23.22 (-5.04-51.49)	0.11	13.19 (-14.62-41.01)	0.35
Premature	29.38 (-0.28-59.04)	0.05	38.99 (-1.47-79.44)	0.06	30.80 (-6.95 - 68.54)	0.11
African American
Late	6.93 (-10.49-24.35)	0.44	9.72(-11.62-31.06)	0.37	1.00(-14.52-16.52)	0.9
Premature	0.04 (-18.57-18.65)	0.997	7.75(-15.33-30.84)	0.51	-9.07(-25.68-7.55)	0.28
Hispanic
Late	5.45 (-8.96 -19.86)	0.46	0.52 (-14.43-15.47)	0.95	-17.24 (-35.39-0.90)	0.06
Premature	5.48 (-11.35 - 22.30)	0.52	4.01(-13.33-21.35)	0.65	-10.68 (-29.91-8.55)	0.28

^*indicates significance at the 0.05 level.

All analyses are in comparison to participants with no family history of CHD, which was the reference group. Model 1 adjusted for age, gender, race/ethnicity, MESA site, and follow-up duration. Model 2 adjusted age, gender, race/ethnicity, MESA site, follow-up duration, education, BMI, hypertension, diabetes mellitus, systolic blood pressure, anti-hypertensive medications, cigarette smoking, LDL-C, and HDL-C. Model 3 adjusted for age, gender, race/ethnicity, MESA site, follow-up duration, education, BMI, hypertension, diabetes mellitus, systolic blood pressure, anti-hypertensive medications, cigarette smoking, LDL-C, HDL-C, and the logarithm of baseline CAC score.